← Back to Screener
Lexaria Bioscience Corp. Common Stock (LEXX)
Price$0.99
Favorite Metrics
Price vs S&P 500 (26W)11.44%
Price vs S&P 500 (4W)34.97%
Market Capitalization$25.53M
All Metrics
Book Value / Share (Quarterly)$0.22
P/TBV (Annual)6.42x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)39.51%
Cash Flow / Share (Quarterly)$-0.40
Price vs S&P 500 (YTD)62.80%
Gross Margin (TTM)99.61%
Net Profit Margin (TTM)-1686.00%
EPS (TTM)$-0.57
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-0.57
Revenue Growth (5Y)17.89%
EPS (Annual)$-0.66
ROI (Annual)-398.09%
Gross Margin (Annual)99.61%
Net Profit Margin (5Y Avg)-1837.15%
Cash / Share (Quarterly)$0.20
ROA (Last FY)-285.07%
Revenue Growth TTM (YoY)5.05%
EBITD / Share (TTM)$-0.56
ROE (5Y Avg)-162.22%
Operating Margin (TTM)-1687.36%
Cash Flow / Share (Annual)$-0.55
P/B Ratio5.20x
P/B Ratio (Quarterly)4.80x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)30.10x
ROA (TTM)-168.35%
EV / EBITDA (TTM)236.11x
EPS Incl Extra (Annual)$-0.66
Current Ratio (Annual)2.32x
Quick Ratio (Quarterly)3.10x
3-Month Avg Trading Volume0.48M
52-Week Price Return-26.43%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.21
P/S Ratio (Annual)36.17x
Asset Turnover (Annual)0.17x
52-Week High$1.69
Operating Margin (5Y Avg)-1896.92%
EPS Excl Extra (Annual)$-0.66
CapEx CAGR (5Y)51.95%
Tangible BV CAGR (5Y)3.67%
26-Week Price Return20.19%
Quick Ratio (Annual)1.56x
13-Week Price Return31.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.68x
Enterprise Value$21.25
Revenue / Share Growth (5Y)-18.92%
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)-28.93%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.50x
Pretax Margin (Annual)-1687.36%
Cash / Share (Annual)$0.10
3-Month Return Std Dev85.77%
Gross Margin (5Y Avg)85.36%
Net Income / Employee (TTM)$-2
ROE (Last FY)-398.09%
EPS Basic Excl Extra (Annual)$-0.66
P/FCF (TTM)111.00x
Receivables Turnover (TTM)4.54x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.57
Receivables Turnover (Annual)4.54x
ROI (TTM)-209.58%
P/S Ratio (TTM)36.17x
Pretax Margin (5Y Avg)-1896.92%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.14
Price vs S&P 500 (52W)-61.52%
Year-to-Date Return66.94%
5-Day Price Return5.10%
EPS Normalized (Annual)$-0.66
ROA (5Y Avg)-137.97%
Net Profit Margin (Annual)-1686.00%
Month-to-Date Return32.05%
Cash Flow / Share (TTM)$-1.13
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-1687.36%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-162.22%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.57
P/TBV (Quarterly)5.12x
P/B Ratio (Annual)5.76x
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)-1687.36%
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)28.85%
Beta0.74x
P/FCF (Annual)111.00x
Revenue / Share (TTM)$0.02
ROE (TTM)-209.58%
52-Week Low$0.46
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LEXXLexaria Bioscience Corp. Common Stock | 36.17x | 5.05% | 99.61% | — | $0.99 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Lexaria Bioscience is a biotechnology company that generates revenue by licensing its proprietary DehydraTECH drug delivery technology, which enhances the bioavailability and effectiveness of active pharmaceutical ingredients. The platform has broad applicability across therapeutics including GLP-1 drugs, pain medications, cannabinoids, and more, serving disease areas like diabetes, weight loss, and hypertension. DehydraTECH can be incorporated into multiple product formats—tablets, capsules, beverages, and foods—for use in pharmaceuticals, nutraceuticals, and consumer products.